Tolerance to 3,4-methylenedioxymethamphetamine is associated with impaired serotonin release

Addiction Biology

Volumn 15, Issue 3, 2010, Pages 289-298

  Jones, Karen ^a   Brennan, Katharine A ^a   Colussi Mas, Joyce ^a   Schenk, Susan ^a  

^a VICTORIA UNIVERSITY OF WELLINGTON   (New Zealand)

Author keywords

Emergence test; Fenfluramine; M CPP; MDMA; RS102221; Tolerance

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 IODO 2,5 DIMETHOXYAMPHETAMINE; 8 [5 [2,4 DIMETHOXY 5 (4 TRIFLUOROMETHYLPHENYLSULFONAMIDO)PHENYL] 5 OXOPENTYL] 1,3,8 TRIAZASPIRO[4.5]DECANE 2,4 DIONE; FENFLURAMINE; SEROTONIN; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; 1-(3-CHLOROPHENYL)PIPERAZINE; 4-IODO-2,5-DIMETHOXYPHENYLISOPROPYLAMINE; AMPHETAMINE DERIVATIVE; PIPERAZINE DERIVATIVE; SEROTONIN AGONIST; SEROTONIN RECEPTOR AFFECTING AGENT;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFECT; FRONTAL CORTEX; HIPPOCAMPUS; HYPOTHALAMUS; LOCOMOTION; MALE; NEUROCHEMISTRY; NONHUMAN; OPEN FIELD TEST; POST HOC ANALYSIS; PRIORITY JOURNAL; RAT; RECEPTOR DOWN REGULATION; SEROTONIN RELEASE; SEROTONINERGIC SYSTEM; ANIMAL; BRAIN; DOSE RESPONSE; DRUG EFFECTS; DRUG TOLERANCE; EXPLORATORY BEHAVIOR; METABOLISM; MOTOR ACTIVITY; REACTION TIME; SPRAGUE DAWLEY RAT;

AMPHETAMINES; ANIMALS; BRAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOLERANCE; EXPLORATORY BEHAVIOR; FENFLURAMINE; MALE; MOTOR ACTIVITY; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; PIPERAZINES; RATS; RATS, SPRAGUE-DAWLEY; REACTION TIME; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTOR, SEROTONIN, 5-HT2C; SEROTONIN; SEROTONIN AGENTS; SEROTONIN RECEPTOR AGONISTS;

EID: 77953177659     PISSN: 13556215     EISSN: 13691600     Source Type: Journal    
DOI: 10.1111/j.1369-1600.2010.00217.x     Document Type: Article

References (69)

1. Abramowski D, Rigo M, Duc D, Hoyer D, Staufenbiel M (1995) Localization of the 5-hydroxytryptamine2C receptor protein in human and rat brain using specific antisera. Neuropharmacology 34 : 1635 1645.
2. Aguirre N, Ballaz S, Lasheras B, Del Rio J (1998) MDMA ('ecstasy') enhances 5-HT1a receptor density and 8-OH-DPAT-induced hypothermia: blockade by drugs preventing 5-hydroxytryptamine depletion. Eur J Pharmacol 346 : 181 188.
3. Aguirre N, Galbete JL, Lasheras B, Del Rio J (1995) Methylenedioxymethamphetamine induces opposite changes in central pre- and postsynaptic 5-HT1A receptors in rats. Eur J Pharmacol 281 : 101 105.
4. Bagdy G, Graf M, Anheuer ZE, Modos EA, Kantor S (2001) Anxiety-like effects induced by acute fluoxetine, sertraline or m-CPP treatment are reversed by pretreatment with the 5-HT2C receptor antagonist SB-242084 but not the 5-HT1A receptor antagonist WAY-100635. Int J Neuropsychopharmacol 4 : 399 408.
5. Baumann MH, Clark RD, Franken FH, Rutter JJ, Rothman RB (2008) Tolerance to 3,4-methylenedioxymethamphetamine in rats exposed to single high-dose binges. Neuroscience 152 : 773 784.
6. Berger UV, Gu XF, Azmitia EC (1992) The substituted amphetamines 3,4-methylenedioxymethamphetamine, methamphetamine, p-chloroamphetamine and fenfluramine induce 5-hydroxytryptamine release via a common mechanism blocked by fluoxetine and cocaine. Eur J Pharmacol 215 : 153 160.
7. Bilkei-Gorzo A, Gyertyan I, Levay G (1998) mCPP-induced anxiety in the light-dark box in rats - a new method for screening anxiolytic activity. Psychopharmacology 136 : 291 298.
8. Bonhaus DW, Weinhardt KK, Taylor M, Desouza A, McNeeley PM, Szcepanski K, Fontana DJ, Trinh J, Rocha CL, Dawson MW, Flippin LA, Eglen RM (1997) RS-102221: a novel high affinity and selective, 5-HT2C receptor antagonist. Neuropharmacology 36 : 621 629.
9. Brennan KA, Schenk S (2006) Initial deficit and recovery of function after MDMA preexposure in rats. Psychopharmacology 184 : 239 246.
10. Bull EJ, Hutson PH, Fone KCF (2003) Reduced social interaction following 3,4-methylenedioxymethamphetamine is not associated with enhanced 5-HT 2C receptor responsivity. Neuropharmacology 44 : 439 448.
11. Bull EJ, Hutson PH, Fone KCF (2004) Decreased social behaviour following 3,4-methylenedioxymethamphetamine (MDMA) is accompanied by changes in 5-HT(2A) receptor responsivity. Neuropharmacology 46 : 202 210.
12. Callaway CW, Wing LL, Geyer MA (1990) Serotonin release contributes to the locomotor stimulant effects of 3,4-methylenedioxymethamphetamine in rats. J Pharmacol Exp Ther 254 : 456 464.
13. Callaway CW, Wing LL, Nichols DE, Geyer MA (1993) Suppression of behavioral activity by norfenfluramine and related drugs in rats is not mediated by serotonin release. Psychopharmacology 111 : 169 198.
14. Cami J, Farre M, Mas M, Roset PN, Poudevida S, Mas A, San L, de la Torre R (2000) Human pharmacology of 3,4-methylenedioxymethamphetamine ('ecstasy'): psychomotor performance and subjective effects. J Clin Psychopharmacol 20 : 455 466.
15. Campbell BM, Merchant KM (2003) Serotonin 2C receptors within the basolateral amygdala induce acute fear-like responses in an open-field environment. Brain Res 993 : 1 9.
16. Colussi-Mas J, Schenk S (2008) Acute and sensitized response to 3,4-methylenedioxymethamphetamine in rats: different behavioral profiles reflected in different patterns of Fos expression. Eur J Neurosci 28 : 1895 1910.
17. Conductier G, Crosson C, Hen R, Bockaert J, Compan V (2005) 3,4-N-methlenedioxymethamphetamine-induced hypophagia is maintained in 5-HT1B receptor knockout mice, but suppressed by the 5-HT2C receptor antagonist RS102221. Neuropsychopharmacology 30 : 1056 1063.
18. Crawley J, Goodwin FK (1980) Preliminary report of a simple animal behavior model for the anxiolytic effects of benzodiazepines. Pharmacol Biochem Behav 13 : 167 170.
19. Dafters RI (1995) Hyperthermia following MDMA administration in rats: effects of ambient temperature, water consumption, and chronic dosing. Physiol Behav 58 : 877 882.
20. Doherty MD, Pickel VM (2000) Ultrastructural localization of the serotonin 2A receptor in dopaminergic neurons in the ventral tegmental area. Brain Res 864 : 176 185.
21. Eberle-Wang K, Mikeladze Z, Uryu K, Chesselet MF (1997) Pattern of expression of the serotonin2C receptor messenger RNA in the basal ganglia of adult rats. J Comp Neurol 384 : 233 247.
22. Fehrer E (1956) The effects on hunger and familiarity of locale on exploration. J Comp Physiol Psychol 49 : 549 552.
23. Fiorella D, Rabin RA, Winter JC (1995) The role of the 5-HT2A and 5-HT2C receptors in the stimulus effects of m-chlorophenylpiperazine. Psychopharmacology 119 : 222 230.
24. Fischer C, Hatzidimitriou G, Wlos J, Katz J, Ricaurte G (1995) Reorganization of ascending 5-HT axon projections in animals previously exposed to the recreational drug (+/-)3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy'). J Neurosci 15 : 5476 5485.
25. Fletcher P, Sinyard J, Higgins GA 2006) The effects of the 5-HT(2C) receptor antagonist SB242084 on locomotor activity induced by selective, or mixed, indirect serotonergic and dopaminergic agonists. Psychopharmacology 187 : 515 525.
26. Gleason SD, Lucaites VL, Shannon HE, Nelson DL, Leander JD (2001) m-CPP hypolocomotion is selectively antagonized by compounds with high affinity for 5-HT(2C) receptors but not 5-HT(2A) or 5-HT(2B) receptors. Behav Pharmacol 12 : 613 620.
27. Graeff F, Netto C, Zangrossi H Jr. 1998) The elevated T-maze as an experimental model of anxiety. Neurosci Biobehav Rev 23 : 237 246.
28. Green AR, Mechan AO, Elliott JM, O'Shea E, Colado MI (2003) The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy'). Pharmacol Rev 55 : 463 508.
29. Grignaschi G, Invernizzi RW, Fanelli E, Fracasso C, Caccia S, Samanin R (1998) Citalopram-induced hypophagia is enhanced by blockade of 5-HT(1A) receptors: role of 5-HT(2C) receptors. Br J Pharmacol 124 : 1781 1787.
30. Hascoet M, Bourin M, Dhonnchadha BA (2001) The mouse light-dark paradigm: a review. Prog Neuropsychopharmacol Biol Psychiatry 25 : 141 166.
31. Heffner TG, Hartman JA, Seiden LS (1980) A rapid method for the regional dissection of the rat brain. Pharmacol Biochem Behav 13 : 453 456.
32. Hughes RN (2007) Neotic preferences in laboratory rodents: issues, assessment and substrates. Neurosci Biobehav Rev 31 : 441 464.
33. Kalivas PW, Duffy P, White SR (1998) MDMA elicits behavioral and neurochemical sensitization in rats. Neuropsychopharmacology 18 : 469 479.
34. Kehne JH, Ketteler HJ, McCloskey TC, Sullivan CK, Dudley MW, Schmidt CJ (1996) Effects of the selective 5-HT2A receptor antagonist MDL 100,907 on MDMA-induced locomotor stimulation in rats. Neuropsychopharmacology 15 : 116 124.
35. Kennett GA, Bailey F, Piper DC, Blackburn TP (1995) Effect of SB 200646A, a 5-HT2C/5-HT2B receptor antagonist, in two conflict models of anxiety. Psychopharmacology 118 : 178 182.
36. Kennett GA, Wood MD, Bright F, Cilia J, Piper DC, Gager T, Thomas D, Baxter GS, Forbes IT, Ham P, Blackburn TP (1996) In vitro and in vivo profile of SB 206553, a potent 5-HT2C/5-HT2B receptor antagonist with anxiolytic-like properties. Br J Pharmacol 117 : 427 434.
37. Kennett GA, Wood MD, Glen A, Grewal S, Forbes I, Gadre A, Blackburn TP (1994) In vivo properties of SB 200646A, a 5-HT2C/2B receptor antagonist. Br J Pharmacol 111 : 797 802.
38. Kleven MS, Assie MB, Koek W (1997) Pharmacological characterization of in vivo properties of putative mixed 5-HT1A agonist/5-HT(2A/2C) antagonist anxiolytics. II. Drug discrimination and behavioral observation studies in rats. J Pharmacol Exp Ther 282 : 747 759.
39. Liechti ME, Baumann C, Gamma A, Vollenweider FX (2000b) Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') are attenuated by the serotonin uptake inhibitor citalopram. Neuropsychopharmacology 22 : 513 521.
40. Liechti ME, Geyer MA, Hell D, Vollenweider FX (2001) Effects of MDMA (ecstasy) on prepulse inhibition and habituation of startle in humans after pretreatment with citalopram, haloperidol, or ketanserin. Neuropsychopharmacology 24 : 240 252.
41. Liechti ME, Saur MR, Gamma A, Hell D, Vollenweider FX (2000a) Psychological and physiological effects of MDMA ('ecstasy') after pretreatment with the 5-HT(2) antagonist ketanserin in healthy humans. Neuropsychopharmacology 23 : 396 404.
42. Liu R, Jolas T, Aghajanian G (2000) Serotonin 5-HT(2) receptors activate local GABA inhibitory inputs to serotonergic neurons of the dorsal raphe nucleus. Brain Res 873 : 34 45.
43. Lucki I, Ward HR, Frazer A (1989) Effect of 1-(m-chlorophenyl)piperazine and 1-(m-trifluoromethylphenyl)piperazine on locomotor activity. J Pharmacol Exp Ther 249 : 155 164.
44. Martin JR, Bos M, Jenck F, Moreau J, Mutel V, Sleight AJ, Wichmann J, Andrews JS, Berendsen HH, Broekkamp CL, Ruigt GS, Kohler C, Delft AM (1998) 5-HT2C receptor agonists: pharmacological characteristics and therapeutic potential. J Pharmacol Exp Ther 286 : 913 924.
45. McGregor IS, Clemens KJ, Van der Plasse G, Li KM, Hunt GE, Chen F, Lawrence AJ (2003) Increased anxiety 3 months after brief exposure to MDMA ('ecstasy') in rats: association with altered 5-HT transporter and receptor density. Neuropsychopharmacology 28 : 1472 1484.
46. Mechan AO, Moran PM, Elliott M, Young AJ, Joseph MH, Green R (2002) A study of the effect of a single neurotoxic dose of 3,4- methylenedioxymethamphetamine (MDMA; 'ecstasy') on the subsequent long-term behaviour of rats in the plus maze and open field. Psychopharmacology 159 : 167 175.
47. Mora PO, Netto CF, Graeff FG (1997) Role of 5-HT2A and 5-HT2C receptor subtypes in the two types of fear generated by the elevated T-maze. Pharmacol Biochem Behav 58 : 1051 1057.
48. Morley KC, Arnold JC, McGregor IS (2005) Serotonin (1A) receptor involvement in acute 3,4-methylenedioxymethamphetamine (MDMA) facilitation of social interaction in the rat. Prog Neuropsychopharmacol Biol Psychiatry 29 : 648 657.
49. Pare WP, Tejani-Butt S, Kluczynski J (2001) The emergence test: effects of psychotropic drugs on neophobic disposition in Wistar Kyoto (WKY) and Sprague Dawley rats. Prog Neuropsychopharmacol Biol Psychiatry 25 : 1615 1628.
50. Paxinos G, Watson C (2005) The Rat Brain in Stereotaxic Coordinates, 5th edn.
51. Peroutka SJ, Newman H, Harris H (1988) Subjective effects of 3,4-methylenedioxymethamphetamine in recreational users. Neuropsychopharmacology 1 : 273 277.
52. Pettibone DJ, Williams M (1984) Serotonin-releasing effects of substituted piperazines in vitro. Biocheml Pharmacol 33 : 1531 1535.
53. Piper BJ, Meyer JS (2004) Memory deficit and reduced anxiety in young adult rats given repeated intermittent MDMA treatment during the periadolescent period. Pharmacol Biochem Behav 79 : 723 731.
54. Pompeiano M, Palacios JM, Mengod G (1994) Distribution of the serotonin 5-HT2 receptor family mRNAs: comparison between 5 and HT2A and 5-HT2C receptors. Brain Res Mol Brain Res 23 : 163 178.
55. Ramos M, Goni-Allo B, Aguirre N (2005) Administration of SCH 23390 into the medial prefrontal cortex blocks the expression of MDMA-induced behavioral sensitization in rats: an effect mediated by 5-HT(2C) receptor stimulation and not by D(1) receptor blockade. Neuropsychopharmacology 30 : 2180 2191.
56. Reneman L, Endert E, de Bruin K, Lavalaye J, Feenstra MG, de Wolff FA, Booij J (2002) The acute and chronic effects of MDMA ('ecstasy') on cortical 5-HT2A receptors in rat and human brain. Neuropsychopharmacology 26 : 387 396.
57. Rudnick G, Wall SC (1992) The molecular mechanism of 'ecstasy' [3,4-methylenedioxy-methamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release. Proc Natl Acad Sci U S A 89 : 1817 1821.
58. Scanzello CR, Hatzidimitriou G, Martello AL, Katz JL, Ricaurte GA (1993) Serotonergic recovery after (+/-)3,4-(methylenedioxy) methamphetamine injury: observations in rats. J Pharmacol Exp Ther 264 : 1484 1491.
59. Scheffel U, Lever JR, Stathis M, Ricaurte GA (1992) Repeated administration of MDMA causes transient down-regulation of serotonin 5-HT2 receptors. Neuropharmacology 31 : 881 893.
60. Schenk S, Hely L, Lake B, Daniela E, Gittings D, Mash DC (2007) MDMA self-administration in rats: acquisition, progressive ratio responding and serotonin transporter binding. Eur J Neurosci 26 : 3229 3236.
61. Schmidt CJ, Taylor VL (1987) Depression of rat brain tryptophan hydroxylase activity following the acute administration of methylenedioxymethamphetamine. Biochem Pharmacol 36 : 4095 4102.
62. Schreiber R, Brocco M, Audinot V, Gobert A, Veiga S, Millan MJ (1995) (1-(2,5-dimethoxy-4 iodophenyl)-2-aminopropane)-induced head-twitches in the rat are mediated by 5-hydroxytryptamine (5-HT) 2A receptors: modulation by novel 5-HT2A/2C antagonists, D1 antagonists and 5-HT1A agonists. J Pharmacol Exp Ther 273 : 101 112.
63. Shankaran M, Gudelsky GA (1999) A neurotoxic regimen of MDMA suppresses behavioral, thermal and neurochemical responses to subsequent MDMA administration. Psychopharmacology 147 : 66 72.
64. Stone DM, Merchant KM, Hanson GR, Gibb JW (1987) Immediate and long-term effects of 3,4-methylenedioxymethamphetamine on serotonin pathways in brain of rat. Neuropharmacology 26 : 1677 1683.
65. Sumnall HR, O'Shea E, Marsden CA, Cole JC (2004) The effects of MDMA pretreatment on the behavioural effects of other drugs of abuse in the rat elevated plus-maze test. Pharmacol Biochem Behav 77 : 805 814.
66. Willins DL, Meltzer HY (1997) Direct injection of 5-HT2A receptor agonists into the medial prefrontal cortex produces a head-twitch response in rats. J Pharmacol Exp Ther 282 : 699 706.
67. Winsauer PJ, McCann UD, Yuan J, Delatte MS, Stevenson MW, Ricaurte GA, Moerschbaecher JM (2002) Effects of fenfluramine, m-CPP and triazolam on repeated-acquisition in squirrel monkeys before and after neurotoxic MDMA administration. Psychopharmacology 159 : 388 396.
68. Wright DE, Seroogy KB, Lundgren KH, Davis BM, Jennes L (1995) Comparative localization of serotonin1A, 1C, and 2 receptor subtype mRNAs in rat brain. J Comp Neurol 351 : 357 373.
69. Zifa E, Fillion G (1992) 5-Hydroxytryptamine receptors. Pharmacol Rev 44 : 401 458.